Posted by Michael Wonder on 22 Dec 2023
Takeda announces China NMPA approval of Livtencity (maribavir) for the treatment of adults with post-transplant cytomegalovirus refractory to prior therapies
21 December 2023 - Approval based on Phase 3 TAK-620-303 SOLSTICE study demonstrating maribavir was superior to conventional therapies at week 8, for primary endpoint.
Takeda today announced that Livtencity (maribavir) has been approved by the National Medical Products Administration of China for the treatment of adult patients with post-hematopoietic stem cell transplant or solid organ transplant cytomegalovirus infection/disease that is refractory to treatment (with or without genotypic resistance) with ganciclovir, valganciclovir, cidofovir or foscarnet.
